Eli Lilly (LLY) Cash from Financing Activities (2009 - 2026)

Eli Lilly has reported Cash from Financing Activities for 18 years, with the latest figure at -$3.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 351.45% year-over-year to -$3.5 billion; the trailing twelve-month figure through Mar 2026 stood at -$7.1 billion (down 341.78% YoY), and the FY2025 full-year result was -$2.2 billion, down 279.92% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$3.5 billion, down from -$2.9 billion in the prior quarter.
• The five-year high for Cash from Financing Activities was $3.5 billion in Q4 2023, with the low at -$3.5 billion in Q1 2026.
• Historically, Cash from Financing Activities has averaged -$374.3 million across 5 years, with a median of -$225.5 million in 2024.
• The largest YoY upside for Cash from Financing Activities was 543.3% in 2025 against a maximum downside of 1176.63% in 2025.
• Eli Lilly's Cash from Financing Activities stood at -$1.1 billion in 2022, then soared by 410.59% to $3.5 billion in 2023, then tumbled by 106.36% to -$225.5 million in 2024, then slumped by 1176.63% to -$2.9 billion in 2025, then fell by 20.54% to -$3.5 billion in 2026.
• The last three Cash from Financing Activities figures came in at -$3.5 billion (Q1 2026), -$2.9 billion (Q4 2025), and $531.0 million (Q3 2025), per Business Quant data.